PROGRAM CHAIR
Craig Hofmeister, MD, MPH
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, GA
PROGRAM DESCRIPTION
This interactive program will provide clinicians who care for people with multiple myeloma with important updates about current and future management of the diseases. It includes two animations and case study discussions.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based oncologists, hematologists, hematology pharmacists, nurse practitioners, and physician’s assistants to ensure confidence in the management of relapsed/refractory multiple myeloma.
LEARNING OBJECTIVES
- Evaluate the outcomes of relapsed/refractory multiple myeloma and the importance of novel mechanisms to address current unmet needs
- Describe the mechanisms of action of bispecific antibodies targeting BCMA in the management of multiple myeloma, as well as the rationale for BCMA as an important target
- Summarize current updates on safety and efficacy data in clinical studies of bispecific antibodies for the management of relapsed/refractory multiple myeloma
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Craig Hofmeister, MD, MPH | Advisory Boards Janssen, AbbVie | Advisory Boards Janssen, AbbVie |
| Contracted Research | Bristol Myers Squibb and Sanofi |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Mike Page, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
- Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]
RELEASED DATE: January 30, 2024
EXPIRATION DATE: January 30, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Craig Hofmeister, MD, MPH
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, GA
PROGRAM DESCRIPTION
This interactive program will provide clinicians who care for people with multiple myeloma with important updates about current and future management of the diseases. It includes two animations and case study discussions.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based oncologists, hematologists, hematology pharmacists, nurse practitioners, and physician’s assistants to ensure confidence in the management of relapsed/refractory multiple myeloma.
LEARNING OBJECTIVES
- Evaluate the outcomes of relapsed/refractory multiple myeloma and the importance of novel mechanisms to address current unmet needs
- Describe the mechanisms of action of bispecific antibodies targeting BCMA in the management of multiple myeloma, as well as the rationale for BCMA as an important target
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .33 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of .33 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Craig Hofmeister, MD, MPH | Advisory Boards | Janssen, AbbVie |
| Contracted Research | Bristol Myers Squibb and Sanofi |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
A medical reviewer from CME Peer Review LLC, has nothing to disclose. - Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Mike Page, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
- Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]
RELEASED DATE: January 30, 2024
EXPIRATION DATE: January 30, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Craig Hofmeister, MD, MPH
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, GA
PROGRAM DESCRIPTION
This interactive program will provide clinicians who care for people with multiple myeloma with important updates about current and future management of the diseases. It includes two animations and case study discussions.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based oncologists, hematologists, hematology pharmacists, nurse practitioners, and physician’s assistants to ensure confidence in the management of relapsed/refractory multiple myeloma.
LEARNING OBJECTIVES
- Summarize current updates on safety and efficacy data in clinical studies of bispecific antibodies for the management of relapsed/refractory multiple myeloma
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .33 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of .33 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Craig Hofmeister, MD, MPH | Advisory Boards | Janssen, AbbVie |
| Contracted Research | Bristol Myers Squibb and Sanofi |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
A medical reviewer from CME Peer Review LLC, has nothing to disclose. - Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Mike Page, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
- Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]
RELEASED DATE: January 30, 2024
EXPIRATION DATE: January 30, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
